Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
WALTHAM, Mass., Nov. 08, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 2:40 p.m. GMT (9:40 a.m. ET).
To access the live webcast, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of the event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
